金斯瑞(01548.HK):高瓴資本入股傳奇生物及認購其認股權證已完成
格隆匯5月23日丨金斯瑞生物科技(01548.HK)公佈,2021年5月14日公吿披露,內容有關(其中包括)購買股份及有關購買事項的視作出售傳奇生物股權,即傳奇生物同意發行及出售而買方LGN Holdings Limited同意購買合共2080.985萬股傳奇股份,總代價為3億美元;及向買方發行傳奇認股權證,可向傳奇生物認購及購買最多合共1000萬股傳奇股份,總行使價為2億美元。
董事會宣佈,認購協議的所有條件已達成,完成已於2021年5月21日(交易時段後,香港時間)發生。完成後,買方持有2080.985萬股傳奇股份與認購傳奇股份的傳奇認股權證。
傳奇完成及悉數行使傳奇認股權證後傳奇生物的股權架構載列如下,並取代該公吿中的股權架構:

LGN Holdings Limited為根據開曼羣島法律註冊成立的獲豁免有限公司,其唯一投資管理人為高瓴資本管理有限公司。
高瓴資本成立於2005年,是一家由投資專業人士和營運行政人員組成的環球企業,專注於建立和投資於實現可持續增長的高品質商業特許經營機構。其獨立的專有研究和行業專長,結合世界一流的運營和管理能力,是高瓴資本投資方式的關鍵。高瓴資本與卓越的企業家和管理團隊合作創造價值,尤其重視於創新和技術轉型。高瓴資本於不同股權投資階段投資於醫療保健、消費、TMT、先進製造業、金融和商業服務行業的企業。高瓴資本及其集團成員代表全球機構客户管理資產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.